1. Wilkes GM, Barton-Burke M. Oncology Nursing Drug Handbook 2006. Sudbury, MA: Jones and Bartlett Publishers; 2006.
2. Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichmanl, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51:1826–1829.
3. Bartelink H, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–2049.
4. Hung A, et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003;97:1195–1202.
5. Flam MS, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized Intergroup study. J Clin Oncol. 1996;16:227–253.
6. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16:279–281.
7. Knox JJ, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332–2338.
8. Bajorin DF, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced carcinoma of the urothelial tract: final report of a phase II trial evaluating 2 dosing schedules. Cancer. 2000;88:1671–1678.
9. Kaufman D, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921–1927.
10. Sternberg CN, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer. 1989;64:2448–2458.
11. Harker WG, et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J Clin Oncol. 1985;3:1463–1470.
12. Logothetis CJ, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050–1055.
13. Vaughn D, et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896). Cancer. 2002;95:1022–1027.
14. Campbell M, Baker LH, Opipari M, al-Sarraf M. Phase II trial with cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma. Cancer Treat Rep. 1981;65:897–899.
15. Kachnic LA, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15:1022–1029.
16. Moore MJ, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441–3445.
17. Roth BJ, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994;12:2264–2270.
18. Vaughn D, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20:937–940.
19. Chu E, DeVita VT. Physicians Cancer Chemotherapy Drug Manual 2007. Sudbury, MA: Jones and Bartlett Publishers; 2007.
20. Wilkes G, Barton-Burke M. Oncology Nursing Drug Handbook 2005. Sudbury, MA: Jones and Bartlett Publishers; 2005, pp. 94–99, 137–140, 222–226, 310–313.
21. Zometa full prescribing information. Novartis Pharmaceuticals Corporation; 2002.
22. Saad F, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–882.
23. Rosen LS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377–387.
24. Kohno N, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:1–8.
25. Rosen LS, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150–3157.
26. Pamidronate full prescribing information. Novartis Pharmaceuticals Corporation; 2005.
27. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–995.
28. Levin VA, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321–324.
29. DeAngelis LM, et al. Malignant gliomas: who benefits from adjuvant chemotherapy. Ann Neurol. 1998;44:691–695.
30. Buckner JC, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251–255.
31. Yung A, et al. Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc Am Soc Clin Oncol. 1999;18:139a.
32. Yung A, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762–2771.
33. Raymond E, et al. Multicenter phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol. 2003;14:603–614.
34. Friedman H, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516–1525.
35. Bear H, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol. 2003;21:4165–4174.
36. Fisher B, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 2000;8:1483–1496.
37. Jones SE, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–5387.
38. Jones S, et al. Final analysis: TC (docetaxel/cyclophosphamide, four cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early breast cancer. Proc SABCS. 2005;(abstract 40).
39. Jones SE, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–5387.
40. Hudis C, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol. 1999;17:93–100.
41. Romond E, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2 positive operable breast cancer: combined analysis of NSABP-B31/NCCTG-N9381. Available at: http://www.asco.org/ac/1.1003,fl12-002511-00fl18-0034-00fl19-005816-00fl21-001,00. Accessed July 2005.
42. Citron M, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003;21:1431–1439.
43. Martin M, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol. 2003;14:833–842.
44. Aisner J, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/− MER) for metastatic carcinoma of the breast: a CALGB study: Cancer and Leukemia Group B. J Clin Oncol. 1987;5: 1523–1533.
45. Bonadonna G, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410.
46. Weiss RB, et al. Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy: analysis of drug dosing and toxicity. Am J Med. 1987;83:455–463.
47. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. JAMA. 1995;273:542–543.
48. Coombes RC, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol. 1996;14:35–45.
49. Marschke RF, et al. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer. 1989;63:1931–1937.
50. Fisher B, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89:1673–1682.
51. Howell A, et al. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial after completion of 5-years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62.
52. Goss PE, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–1271.
53. Coombes RC, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092.
54. Sledge GE, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol. 2003;21:588–592.
55. Levine MN, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16:2651–2658.
56. O’Shaughnessy J, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2123–2812.
57. Biganzoli L, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7(Suppl 6):29–35.
58. Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology. 1997;11:31–33.
59. Brufman G, et al. Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates: an international randomized phase III in metastatic breast cancer: the Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol. 1997;8:155–162.
60. Acuna LR, et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 1999;17:74–81.
61. Spielman M, et al. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol. 1994;12:1764–1770.
62. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
63. Goldenberg MM, et al. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21:309–318.
64. Francisco E, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER2 overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800–1808.
65. O’Shaughnessy J, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol. 2003;22:7(abstract 25).
66. Perez EA, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88:124–131.
67. Fitch V, et al. N9332: phase II cooperative group trial of docetaxel (D) and carboplatin (CBCDA) as first-line chemotherapy for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2003;22:23(abstract 90).
68. Ixempra (isabepilone) for injection full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; October 2007.
69. Tykerb (lapatinib) tablets full prescribing information. Research Triangle Park, NC: GlaxoSmithKline; March 2007.
70. Garewal HS, et al. Treatment of advanced breast cancer with mitomycin-C combined with vinblastine or vindesine. J Clin Oncol. 1983;1:772–775.
71. Jaiyesimi IA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13:513–529.
72. Hayes DF, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13:2556–2566.
73. Lonning PE, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors, a phase I trial. J Clin Oncol. 2000;18:2234–2244.
74. Buzdar A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase II trials. Arimidex Study Group. J Clin Oncol. 1996;14:2000–2011.
75. Dombernowsky P, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453–461.
76. Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(Suppl 12):4402s–4410s.
77. Kimmick GG, Muss HB. Endocrine therapy in breast cancer. Cancer Treat Res. 1998;94:231–254.
78. Baselga J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin™) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(Suppl 12):78–83.
79. Baselga J, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23:2162–2171.
80. Blum JL, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–493.
81. Chan S. Docetaxel vs. doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology. 1997;11(Suppl 8):19–24.
82. Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist. 2001;6(Suppl 3):26–29.
83. Holmes FA, et al. Phase II trial of Taxol™, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83:1797–1805.
84. Perez EA. Paclitaxel in breast cancer. Oncologist. 1998;3:373–389.
85. Fumoleau P, Delozier T, Extra JM, Canobbio L, Delgado FM, Hurteloup P. Vinorelbine (Navelbine®) in the treatment of breast cancer: the European experience. Semin Oncol. 1995;22(Suppl 5):22–28.
86. Torti FM, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med. 1983;99:745–749.
87. Carmichael J, et al. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996;23(Suppl 10):77–81.
88. Ranson MR, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol. 1997;15:3185–3191.
89. O’Shaughnessy J, et al. ABI-007 (ABRAXANE), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs. Taxol™ in MBC: a phase III trial. Breast Cancer Res Treat. 2003;82:(Suppl 1)(abstract 43).
90. O’Shaughnessy JA, et al. Weekly nanoparticle albumin paclitaxel (Abrax-ane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. Breast Cancer Res Treat. 2004;88:(Suppl 1):S65 (abstract 1070).
91. Hainsworth JD, et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol. 1997;15:2385–2393.
92. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma: a study by the EORTC lung cancer working party. Cancer. 1982;50:2751–2756.
93. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992;10:912–922.
94. Greco FA, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research network study. J Clin Oncol. 2002;20:1651–1656.
95. Moertel CG, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–526.
96. Moertel CG, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer. 1991;68:227–232.
97. Saltz L, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244.
98. Sandostatin LAR full prescribing information. Novartis Pharmaceuticals Corporation; February 2005.
99. Rubin J, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:606–660.
100. Rose PG, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1995;15:1144.
101. Morris M, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143.
102. Fiorica J, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinoma of the cervix. Gynecol Oncol. 2002;85:89–94.
103. Buxton EJ, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81:359–361.
104. Murad AM, Triginelli SA, Ribalta JC. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12:55–59.
105. Whitney CW, et al. Randomized comparison of fluorouracil plus cis-platin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339–1348.
106. Pignata S, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999;17:756–760.
107. Chitapanarux I, et al. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89:402–407.
108. Vogl SE, et al. Chemotherapy for advanced cervical cancer with bleomycin, vincristine, mitomycin-C, and cisplatinum (BOMP). Cancer Treat Rep. 1980;64:1005–1007.
109. Alberts DS, Garcia DJ. Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix. Semin Oncol. 1994;21(Suppl 7):37–46.
110. Levy T, et al. Advanced squamous cell cancer (SCC) of the cervix: a phase II study of docetaxel (Taxotere™) 100 mg/m2 intravenously (IV) over 1 hour every 21 days: a preliminary report. Proc Am Soc Clin Oncol. 1996;15:292a.
111. Thigpen T, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997;24(Suppl 2):41–46.
112. Verschraegen CF, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15: 625–631.
113. Lacava JA, et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol. 1997;15:604–609.
114. Muderspach LI, et al. A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2001;81:213–215.
115. Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740.
116. Minsky BD. Combined modality therapy of rectal cancer with oxaliplatin-based regimens. Clin Colorectal Cancer. 2004;4(Suppl 1):S29–S36.
117. O’Connell MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246–250.
118. Wolmark N, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol. 1993;11:1879–1887.
119. Benson AB, et al. NCCN practice guidelines for colorectal cancer. Oncology. 2000;14:203–212.
120. de Gramont A, et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. Proc Am Soc Clin Oncol. 2003;22:253(abstract 1015).
121. Cassidy J, et al. Capecitabine (X) vs. bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial. Proc Am Soc Clin Oncol. 2004;23:(abstract 3509).
122. Saltz LB, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905–914.
123. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
124. Hwang JJ, et al. Capecitabine-based combination chemotherapy. Am J Oncol Rev. 2003;2(Suppl 5):15–25.
125. Douillard JY, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041–1047.
126. Andre T, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer. 1999;35:1343–1347.
127. de Gramont A, et al. Leucovorin and fluorouracil with and without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
128. Tournigand C, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol. 2001;20:124a(abstract 494).
129. Andre T, et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized Optimox study. Proc Am Soc Clin Oncol. 2003;22:253(abstract 1016).
130. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345.
131. Scheithauer W, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003;21:1307–1312.
132. Kerr D. Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. Oncology. 2002;16(Suppl 14):12–15.
133. Goldberg RM, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.
134. Poon MA, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407–1418.
135. Petrelli N, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial: Gastrointestinal Tumor Study Group. J Clin Oncol. 1989;7:1419–1426.
136. Kabbinavar F, et al. Results of a randomized phase II controlled trial of bevacizumab in combination with 5-fluorouracil and leucovorin as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol. 2004;23:(abstract 3516).
137. Jager E, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial: Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol. 1996;14:2274–2279.
138. de Gramont A, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol. 1997;15:808–815.
139. Mitchell EP, et al. High-dose bevacizumab in combination with FOL-FOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27–29, 2005, Hollywood, FL (abstract 169a).
140. Hochster HS, et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized “TREE-2” trial. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27–29, 2005, Hollywood, FL (abstract 241).
141. Blanke, CD, Kasimis B, Schein P Capizzi R, Kurman M. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol. 1997;15:915–920.
142. Kemeny N, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 1994;12:2288–2295.
143. Hoff P et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;15:2282–2292.
144. Pitot HC, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997;15:2910–2919.
145. Ulrich-Pur H, et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol. 2001;12:1269–1272.
146. Rougier P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251–260.
147. Saltz LB, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expressed the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208.
148. Vectibix (panitumimab) for injection full prescribing information. Thousand Oaks, CA: Amgen, Inc.; September 2006.
149. Leichman CG, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwestern Oncology Group study. J Clin Oncol. 1995;13:1303–1311.
150. Leichman CG. Schedule dependency of 5-fluorouracil. Oncology. 1999;13(Suppl 3):26–32.
151. Hoskins PJ, et al. Paclitaxel and carboplatin alone or with radiation in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19:4048–4053.
152. Thigpen JT, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1408–1414.
153. Deppe G, et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynecol Oncol. 1994;15: 263–266.
154. Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7(Suppl 5):36–45.
155. Fleming GF, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159–2165.
156. Burke TW, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55:47–50.
157. Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21:107–113.
158. Thigpen JT, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736–1744.
159. Ball H, et al. A phase II trial of paclitaxel with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62:278–282.
160. Wadler S, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group study E3E93. J Clin Oncol. 2003;21:2110–2114.
161. Ramirez PT, et al. Hormonal therapy for the management of grade1 endometrial adenocarcinoma, a literature review. Gynecol Oncol. 2004;95: 133–138.
162. Herskovic A, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598.
163. Heath El, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol. 2000;18:868–876.
164. Kies MS, et al. Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer. 1987;60:2156–2160.
165. Ilson DH, et al. Phase II trial of weekly irinotecan plus cisplatin in first line advanced esophageal cancer. J Clin Oncol. 1999;17:3270–3275.
166. Ilson DH, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826–1834.
167. Lin LL, Edward H, Lozano R, Karp D. Color-Matrix Cancer Staging and Treatment Handbook, 3rd ed. Houston, TX: University of Texas MD Anderson; 2004, p. 75.
168. Ajani JA, et al. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol. 1995;22(Suppl 6):35–40.
169. MacDonald JS, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730.
170. Ajani JA, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V3325). Proc Am Soc Clin Oncol. 2003;22:249(abstract 999).
171. Wilke M, et al. Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol. 1989;7:1318–1326.
172. Findlay M, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994;5:609–616.
173. Wilke M, et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO. Proc Am Soc Clin Oncol. 1995;14:206a.
174. Shirao K, Shimada Y, Kondo H, et al. Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol. 1997;15:921–927.
175. MacDonald JS, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980;93:533–536.
176. Kelsen D, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992;10:541–548.
177. Cullinan SA, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer: North Central Cancer Treatment Group. J Clin Oncol. 1994;12:412–416.
178. Ajani JA, et al. Multinational randomized trial of docetaxel, cisplatin with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma. Proc Am Soc Clin Oncol. 2000;20:165a (abstract 657).
179. Ajani, JA, Fodor, MD, Tjulandin, SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660.
180. O’Connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol. 1985;3:1032–1039.
181. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology. 2002;16(Suppl 6):89–96.
182. Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.
183. Sutent [package insert]. New York: Pfizer Inc.; 2006. Available at http://www.pfizer.com/pfizer/download/uspi_sutent.pdf. Accessed March 1, 2006.
184. Shin DM, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:1325–1330.
185. Posner M, et al. Multicenter phase I–II trial of docetaxel, cisplatin, and flu-orouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19:1096–1104.
186. Shin DM, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma of the head and neck (SCCHN). Cancer. 1999;91:1316–1323.
187. Fountzilas G, et al. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. Semin Oncol. 1997;24(Suppl 2):65–67.
188. Hitt R, et al. A phase I/II study of paclitaxel plus cisplatin as firstline therapy for head and neck cancer. Semin Oncol. 1995;22(Suppl 15):50–54.
189. Kish JA, et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer. 1984;53:1819–1824.
190. Vokes EE, et al. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989;63(Suppl 6):1048–1053.
191. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–1690.
192. Forastiere AA, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098.
193. Al-Sarraf M, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–1317.
194. Forastiere AA, et al. Randomized comparison of cisplatin plus fluo-rouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245–1251.
195. Gebbia V, et al. Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. Am J Clin Oncol. 1995;18:293–296.
196. Dreyfuss A, et al. Taxotere for advanced, inoperable squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol. 1995;14:875a.
197. Forastiere AA. Current and future trials of Taxol™ (paclitaxel) in head and neck cancer. Ann Oncol. 1994;5(Suppl 6):51–54.
198. Hong WK, et al. Chemotherapy in head and neck cancer. N Engl J Med. 1983;308:75–79.
199. Degardin M, et al. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 1998;9:1103–1107.
200. Chua DT, et al. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal cancer pretreated with platinum-based chemotherapy. Oral Oncol. 2003;39:361–366.
201. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol. 1994;12:1323–1334.
202. Okada S, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology. 1993;50:22–26.
203. Aguayo A, et al. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol. 2001;28:503–513.
204. Ireland-Gill A, et al. Treatment of acquired immunodeficiency syndrome-related Kaposi’s sarcoma using bleomycin-containing combination chemotherapy regimens. Semin Oncol. 1992;19(Suppl 5):32–37.
205. Laubenstein LL, et al. Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol. 1984;2:1115–1120.
206. Gill PS, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol. 1996;14:2353–2364.
207. Northfelt DW, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997;15:653–659.
208. Gill PS, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol. 1999;17:1876–1880.
209. Gill PS, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi’s sarcoma. Cancer. 2002;95:147–154.
210. Real FX, Oettgen HF, Krown SE. Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low dose of recombinant leucocyte A interferon. J Clin Oncol. 1986;4:544–551.
211. Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:671–676.
212. Linker CA, et al. Improved results of treatment of adult acute lymphoblastic leukemia. Blood. 1987;69:1242–1248.
213. Linker CA, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991;78: 2814–2822.
214. Larson R, et al. A five-drug regimen remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood. 1995;85:2025–2037.
215. Kantarjian H, et al. Results of treatment with hyper-CVAD, a dose intensive regimen in adult acute lymphoblastic leukemia. J Clin Oncol. 2000;18:547–561.
216. Faderl S, et al. The role of clofarabine in hematologic and solid malignancies: development of a next generation nucleoside analog. Cancer. 2005;103:1985–1995.
217. Gleevec (imatinib mesylate) tablets full prescribing information. East Hanover, NJ: Novartis Pharmaceutical Corporation; Rev. October 2006.
218. Yates JW, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57:485–488.
219. Preisler H, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: Cancer and Leukemia Group B study. Blood. 1987;69:1441–1449.
220. Preisler H, et al. Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia. Cancer Treat Rep. 1977;61:89–92.
221. Wiernik PH, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313–319.
222. Santana VM, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992;10:364–369.
223. Mayer RJ, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903.
224. Sievers EL, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti CD33 calicheamycin immunoconjugate. Blood. 1999;11:3678–3684.
225. Ho AD, Lipp T, Ehninfer G, Meyer P Freund M, Hunstein W. Combination therapy with mitox-antrone and etoposide in refractory acute myelogenous leukemia. Cancer Treat Rep. 1986;70:1025–1027.
226. Montillo M, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol. 1998;58: 105–109.
227. Mandelli F, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90:1014–1021.
228. Trisenox© [package insert]. Seattle, WA: Cell Therapeutics, Inc.; 2003. Trisenox© (arsenic trioxide) injection Nursing Advisory Board Meeting Summary, April 2004. Seattle, WA: Cell Therapeutics, Inc.; 2004.
229. Degos L, et al. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995;85:2643–2653.
230. Raphael B, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Co-operative Oncology Group randomized clinical trial. J Clin Oncol. 1991;9:770–776.
231. Keating MJ, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165–1171.
232. O’Brien S, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;82: 1695–1700.
233. Byrd JC, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B9712. Blood. 2003;101:6–14.
234. Keating MJ, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for CLL. J Clin Oncol. 2005;22:4079–4088.
235. Osterborg A, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol. 1997;15:1567–1574.
236. Dighiero G, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998;338:1506–1514.
237. Saven A, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13:570–574.
238. Keating MJ, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19–25.
239. Sawitsky A, Rai KR, Glidewell O, Silver RT. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 1977;50:1049.
240. Treanda (bendamustine HCL) for injection dull prescribing information. Cephalon Inc., Frazer, PA; March 2008.
241. Guilhot F, et al. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223–229.
242. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myelogenous leukemia. N Engl J Med. 2001;344:1031–1037.
243. Hehlmann R, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea: the German CML Study Group. Blood. 1993;82:398–407.
244. Hehlmann R, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia: German CML Study Group. Blood. 1994;84:4064–4077.
245. The Italian Cooperative Study Group on Chronic Myelogenous Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820–825.
246. Talpaz M. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemia. N Engl J Med. 2006;354:2531–2541.
247. Sprycel [package insert]. Sprycel (dastinib) tablets. Princeton, NJ: Bristol-Myers Squibb Company.
248. Tasigna (nilotinib) capsules full prescribing information. East Hanover, NJ: Novartis Pharmaceutical Corporation; October 2007.
249. Ontak full prescribing information. Ridgefield Park, NJ: Eisai Inc.; February 2007.
250. Saven A, Piro LD. Treatment of hairy cell leukemia. Blood. 1992;79: 1110–1120.
251. Cassileth PA, et al. Pentostatin induces durable remission in hairy cell leukemia. J Clin Oncol. 1991;9:243–246.
252. Ratain MJ, et al. Treatment of hairy cell leukemia with recombinant alpha-2 interferon. Blood. 1985;65:644–648.
253. Strauss GM, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer: CALGB 9633. J Clin Oncol. 2004;621S(abstract 7019).
254. Winton T, et al. Vinorelbine plus cisplatin versus observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:2589–2597.
255. Langer CJ, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13:1860–1870.
256. Giaccone G, et al. Randomized study of paclitaxel-cisplatin versus cis-platin-teniposide in patients with advanced non-small cell lung cancer: the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998;16:2133–2141.
257. Fossella F, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group. J Clin Oncol. 2003;21:3016–3024.
258. Belani CP, et al. Docetaxel and cisplatin in patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II trial. Clin Lung Cancer. 1999;1:144–150.
259. Georgoulias V, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial. Lancet. 2001;357:1478–1484.
260. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol. 1997;15:744–749.
261. Langer CJ, et al. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Semin Oncol. 1999;26(Suppl 4):12–18.
262. Frasci G, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 2000;18:2529–2536.
263. Smith TJ, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cis-platin for non-small cell lung cancer. J Clin Oncol. 1995;13:2166–2173.
264. Cremonesi M, et al. Vinorelbine and carboplatin in operable non-small lung cancer: a mono-institutional phase II study. Oncology. 2003;64(2): 97–101.
265. Longeval E, et al. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma: a study by the EORTC lung cancer working party. Cancer. 1982;50: 2751–2756.
266. Gandara D, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003;21:2004–2010.
267. Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355(24):2050–2542.
268. Lilenbaum RC, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol. 2005;23:190–196.
269. Tester WJ, et al. Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer. 1997;79:724–729.
270. Miller VA, et al. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol. 2000;27(Suppl 3):3–10.
271. Hainsworth JD, et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer. Cancer. 2000;89:328–333.
272. Hanna N, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597.
273. Manegold C, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol. 1997;8:525–529.
274. Perez-Soler R, et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996;14:503–513.
275. Furuse K, et al. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small cell lung cancer (NSCLC): the Japan Vinorelbine Lung Cancer Cooperative Study Group. Ann Oncol. 1996;7:815–820.
276. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol. 2003;30(Suppl 1):30–38.
277. Shepherd FA, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st and 2nd line chemotherapy: a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol. 2004;22 (Suppl 1):14S(abstract 7022).
278. Ihde DC, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol. 1994;12:2022–2034.
279. Viren M, et al. Carboplatin and etoposide in extensive small cell lung cancer. Acta Oncol. 1994;33:921–924.
280. Noda K, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med. 2002;346: 85–91.
281. Hainsworth JD, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol. 1997;15:3464–3470.
282. Roth BJ, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–291.
283. Aisner J, et al. Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small cell carcinoma of the lung. Semin Oncol. 1986;(Suppl 3):54–62.
284. Johnson DH. Recent developments in chemotherapy treatment of small cell lung cancer. Semin Oncol. 1993;20:315–325.
285. Johnson DH, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol. 1990;8:1013–1017.
286. Hainsworth JD, et al. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. Semin Oncol. 1999;26(Suppl 2):60–66.
287. Ardizzoni A, et al. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease: the European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090–2096.
288. Bonadonna G, et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–259.
289. DeVita VT, Jr, et al. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73:881–895.
290. Klimo P, et al. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease. J Clin Oncol. 1985;3:1174–1182.
291. Canellos GP, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327(21):1478–1484.
292. Bartlett NL, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol. 1995;13:1080–1088.
293. Diehl V, et al. BEACOPP, a new dose-escalated and accelerated regimen is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma. J Clin Oncol. 1998;16:3810–3821.
294. Tesch H, et al. Moderate dose escalation for advanced Hodgkin’s disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin’s Lymphoma Study Group. Blood. 1998;15:4560–4567.
295. Radford JA, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin’s disease. J Clin Oncol. 1995;13:2379–2385.
296. Longo DL. The use of chemotherapy in the treatment of Hodgkin’s disease. Semin Oncol. 1990;17:716–735.
297. Colwill R, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13:396–402.
298. Santoro A, et al. Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol. 2000;18: 2615–2619.
299. Bagley CM, Jr, et al. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med. 1972;76:227–234.
300. Hochster HS, et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) (abstract). J Clin Oncol. 2004;22(abstract 6502).
301. Sonnevald P et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995; 13:2530–2539.
302. McLaughlin P, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996;14: 1262–1268.
303. Hochster H, et al. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first-line therapy of low-grade non-Hodgkin’s lymphoma (NHL). Blood. 1994;84 (Suppl 1):383a.
304. McKelvey EM, et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–1493.
305. Vose JM, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:389–397.
306. Wilson WH, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1993;11: 1573–1582.
307. Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol. 2000;27(Suppl 12):30–36.
308. Klimo P, et al. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med. 1985;102:596–602.
309. Shipp MA, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986;104:757–765.
310. Longo DL, et al. Superiority of ProMACE-CytaBOM over Pro-MACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991;9:25–38.
311. Magrath I, et al. An effective therapy for both undifferentiated lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–1111.
312. Magrath I, et al. Adults and children with small non-cleaved cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14:925.
313. Berstein JI, et al. Combined modality therapy for adults with small non-cleaved cell lymphoma (Burkitt’s and non-Burkitt’s types). J Clin Oncol. 1986;4:847–858.
314. Goy AH, et al. Report of a phase II study of proteosome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas. Proc Am Soc Clin Oncol. 2003;22:570(abstract 2291).
315. Coiffier B, et al. Rituximab plus CHOP in combination with CHOP chemotherapy in patients with diffuse large B-cell lymphoma: an update of the GELA study. N Engl J Med. 2002;346:235–242.
316. Vose JM, et al. CNOP for diffuse aggressive non-Hodgkin’s lymphoma: the Nebraska Lymphoma Study Group experience. Leuk Lymphoma. 2002;43:799–804.
317. Velasquez WS, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–1176.
318. Velasquez WS, et al. Effective salvage therapy for lymphoma with cis-platin in combination with high-dose ara-C and dexamethasone. Blood. 1988;71:117–122.
319. Moskowitz C, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral blood progenitor cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3776–3785.
320. Rodriguez MA, et al. A phase II trial of mesna/ifosfamide, mitoxantrone, and etoposide for refractory lymphoma. Ann Oncol. 1995;6:609–611.
321. Abrey LE, et al. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144–3150.
322. McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833.
323. Witzig TE, et al. Randomized controlled trial of yttrium-90-labeled ibri-tumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463.
324. Falkson CI. A phase II trial in patients with previously treated low-grade lymphoma.Am J Clin Oncol. 1996;19:268–270.
325. Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 1998;16:850–858.
326. Bexxar [package insert]. Research Triangle Park, NC: Glaxo SmithKline; October 2005.
327. Zolinza (vorinostat) capsules full prescribing information. Whitehouse Station, NJ: Merck and Co., Inc.; October, 2006.
328. Kirkwood JM, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Trial EST 1684. J Clin Oncol. 1996;14:7–17.
329. Creagen ET, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999;17:1884–1890.
330. DelPrete SA, et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984;68:1403–1405.
331. Legha SS, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and DTIC (CVD) for metastatic melanoma. Cancer. 1989;64:2024–2029.
332. Falkson CI, et al. Phase III trial of dacarbazine vs. dacarbazine with interferon α-2b vs. dacarbazine with tamoxifen vs. dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma. J Clin Oncol. 1998;16:1743–1751.
333. Eton O, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045–2052.
334. Hwu WJ, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose finding trial. J Clin Oncol. 2002; 20:2607–2609.
335. Luce JK, et al. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388). Cancer Chemother Rep. 1970;54:119–124.
336. Pritchard KI, et al. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep. 1980;64:1123–1126.
337. Kirkwood JM, et al. Advances in the diagnosis and treatment of malignant melanoma. Semin Oncol. 1997;24(Suppl 4):1–48.
338. Parkinson DR, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol. 1990;8:1650–1656.
339. Middleton MR, et al. Randomized phase II study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–166.
340. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cis-platin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. Cancer. 1991;67:2984–2987.
341. Shin DM, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer. 1995;76:2230–2236.
342. Nowak AK, et al. A multicentre phase II study of cisplatin and gem-citabine for malignant mesothelioma. Br J Cancer. 2002;87:491–496.
343. Favaretto AG, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer. 2003;97:2791–2797.
344. Vogelzang NJ, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
345. Southwest Oncology Group Study. Remission maintenance therapy for multiple myeloma. Arch Intern Med. 1975;135:147–152.
346. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310: 1353–1356.
347. Rajkumar SV, et al. Combination therapy with thalidomide plus dexameth-asone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319–4323.
348. Case DC, Jr, et al. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, and BCNU. Am J Med. 77;63:897–903.
349. Oken MM, et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer. 1997;79(8):1561–1567.
350. Orlowski RZ, et al. Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone improves time to progression in relapsed or refractory multiple myeloma: results from DOXIL-MMY-3001. J Clin Oncol. 2007;25:5460–5469.
351. Wever DM, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.
352. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105:8–11.
353. Cunningham D, et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol. 1994;12:764–768.
354. Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565–1571.
355. Richardson P, et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617.
356. Browman GP, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1995;13:2354–2360.
357. Kaminskas E, et al. Approval summary: azacytidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 2005;11: 3604–3608.
358. List A, et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 2003;17:1499–1507.
359. List A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.
360. Dacogen (decitabine for injection) [package insert]. Bloomington, MN: MGI Pharma, Inc.; May 2006.
361. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol. 2005;42(3 Suppl 2):S17-S22.
362. Swenerton K, et al. Cisplatin-cyclophosphamide versus carboplatin cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992;10:718–726.
363. Alberts D, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwestern Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10:706–717.
364. McGuire WP, et al. Cyclophosphamide and cisplatin compared with pa-clitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
365. Ozols RE. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995;22 (Suppl 15):1–6.
366. Markman M, et al. Combination chemotherapy with carboplatin and doc-etaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19:1901–1905.
367. D’Agostino G, et al. Phase II study of liposomal doxorubicin and gemc-itabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89: 1180–1184.
368. Nagourney RA, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated relapsed ovarian cancer patients. Gynecol Oncol. 2003;88:35–39.
369. Jacobus Pfisterer, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol. 2006;24:4699–4707.
370. Armstrong DK, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
371. Walker JL, et al. Intraperitoneal catheter outcomes in phase III trial of intravenous verses intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecological oncology group study. Gynecol Oncol. 2006;100:27–32.
372. Markman M. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a gynecologic oncology group phase II trial. Gynecol Oncol. 1998;69:226–229.
373. Gordon AN, et al. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000; 18:3093–3100.
374. McGuire WP, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989; 111:273–279.
375. Kudelka AP, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996; 14:1552–1557.
376. Lund B, Hansen OP, Theilade K, Hansen M, Neijt NP. Phase II study of gemcitabine (2929-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86:1530–1533.
377. Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999;58(Suppl 3):43–49.
378. Dimopoulos MA, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multi-center study. Gynecol Oncol. 2004;95:695–700.
379. Gastrointestinal Tumor Study Group. Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 1979;5:1643–1647.
380. DeCaprio JA, et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991;9:2128–2133.
381. Hess V, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol. 2003; 21:66–68.
382. Fine RL, et al. The GTX regimen: a biochemically synergistic combination for advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol. 2003;22:281(abstract 1129).
383. Heinemann V. Randomized phase III of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3951.
384. Epelbaum K, et al. Gemcitabine and cisplatin with advanced pancreatic cancer. Proc J Clin Oncol. 2003;22:1202.
385. Ko AH, et al. Phase II study of fixed-dose rate gemcitabine with cisplatin formetastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006;24:327–329.
386. Poplin E, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2006;24:1805.
387. Louvet C, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002;20:1512–1518.
388. Rocha-Lima C, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA19–9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20:1182–1191.
389. Leonard RC, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Cancer. 1994;81:882–885.
390. Moore MJ, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the NCIC-CTG. J Clin Oncol. 2005;23:16S(abstract 1).
391. No authors listed. Phase II studies of drug combinations in advanced pancreatic carcinoma 5-fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus 5-fluorouracil: the Gastrointestinal Study Goup. J Clin Oncol. 1986;4:1794–1798.
392. Burris HA, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
393. Brand R, et al. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997;15:331–341.
394. Cartwright TH, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002;20:160–164.
395. Eisenberger MA, et al. Prognostic factors in stage D2 prostate cancer: important implications for future trials; results of a cooperative Inter-group study (INT.0036): the National Cancer Institute Intergroup Study #0036. Semin Oncol. 1994;21:613–619.
396. Jurincic CD, et al. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study. Semin Oncol. 1991;18(Suppl 6):21–25.
397. Pienta KJ, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994;12:2005–2012.
398. Hudes GR, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992;11:1754–1761.
399. Hudes GR, et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 1995;22(Suppl 12):41–45.
400. Tannock IF, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764.
401. Petrylak DP. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958–967.
402. Eisenberger MA, et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol. 2004;23:2(abstract 4).
403. Roth BJ, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2260–2457.
404. Ahmed S, et al. Feasibility of weekly 1 hour paclitaxel in hormone-refractory prostate cancer (HRPC): a preliminary report of a phase II trial. Proc Am Soc Clin Oncol. 1998;17:325a.
405. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol. 2000;27(Suppl 3):24–29.
406. Murphy GP, et al. Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial Institute. Urology. 1984;23:54–63.
407. Dijkman GA, Debruyne FM, Fernandez del Moral P, et al. A randomized trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer: the Dutch South East Cooperative Urological Group. Eur Urol. 1995;27:43–46.
408. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311:1281–1286.
409. Sharifi R, et al. Leuprolide acetate 22.5-mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996;18:647–657.
410. Schellhammer PF, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multi-center trial: Casodex Combination Study Group. Urology. 1997;50:330–336.
411. McLeod DG, et al. The use of flutamide in hormone-refractory metastatic prostate cancer. Cancer. 1993;72:3870–3873.
412. Janknegt RA, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993;149:77–82.
413. Johnson DE, et al. Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology. 1988;31:132–134.
414. Havlin KA, et al. Aminoglutethimide: theoretical considerations and clinical results in advanced prostate cancer. Cancer Treat Res. 1988; 39:83–96.
415. Atzpodien J, et al. European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol. 1993;20(Suppl 9):22.
416. Rini BI, et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol. 2000;18:2419–2426.
417. Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696.
418. Minasian LM, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11:1368–1375.
419. Motzer RJ, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;223: 454–463.
420. Motzer RJ, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24:16–24.
421. Torisel (temsirolimus) for injection, full prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; May 2007.
422. Antman K, et al. An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276–1285.
423. Elias A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989;7:1208–1216.
424. Santoro A, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer, Soft Tissue, and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537–1545.
425. Grier HE, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701.
426. Merimsky O, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol. 2000;45:177–181.
427. Einhorn LH, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group Protocol. J Clin Oncol. 1989;7:387–391.
428. Williams SD, et al. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–1440.
429. Bosl G, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol. 1988;6:1231–1238.
430. Einhorn LH, et al. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87:293–298.
431. Vugrin D, et al. VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann Intern Med. 1981;95:59–61.
432. Motzer RJ, et al. Salvage chemotherapy for patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience. Cancer. 1991;67:1305–1310.
433. Loehrer PJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988;109:540–546.
434. deWit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol. 2006; 24:5482–5492.
435. Loehrer PJ, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an Intergroup trial. J Clin Oncol. 1994;12:1164–1168.
436. Giaccone G, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study of the European Organization for Research and Treatment of Lung Cancer Cooperative Group. J Clin Oncol. 1996;14:814–820.
437. Fornasiero A, et al. Chemotherapy for invasive thymoma. Cancer. 1991;68:30–33.
438. Shimaoka K, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155–2160.